MerLion's lead drug finafloxacin moves into Phase III through Alcon
This article was originally published in Scrip
MerLion Pharmaceuticals' most advanced therapeutic product, the broad-spectrum fluoroquinolone antibiotic finafloxacin, has moved into its first Phase III clinical trials, in the US and Canada for the treatment of ear infections.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.